Could a sphingosine nasal spray prevent COVID-19?
According to a study, the lipid sphingosine can inhibit SARS-CoV-2 infection and could potentially be delivered in a nasal spray to prevent COVID-19 infections.
List view / Grid view
According to a study, the lipid sphingosine can inhibit SARS-CoV-2 infection and could potentially be delivered in a nasal spray to prevent COVID-19 infections.
New research has shown that MAIT cells are strongly activated in people with moderate to severe COVID-19 disease.
Pre-clinical studies in cells and hamsters have shown that potent antibodies from COVID-19 patients can prevent infection from SARS-CoV-2.
Scientists reveal that some patients who develop severe COVID-19 symptoms mount ineffective immune responses due to a lack of type I interferons, either through genetic mutation or inactivation by auto-reactive antibodies.
A new interactive map of the surface of SARS-CoV-2, featuring the Spike, Envelope and Membrane proteins, has been released for researchers to use.
Researchers have identified two molecules that explain why children experience COVID-19 differently to adults.
Scientists have demonstrated that AR-12 can inhibit SARS-CoV-2 replication and are working to initiate clinical trials evaluating the antiviral drug.
Scientists have developed a new assay that uses nanoparticles to mimic how SARS-CoV-2 infects a cell, which could be used to screen for drugs that treat COVID-19.
A pocket in the SARS-CoV-2 Spike protein has been discovered by researchers, who say it could be a drug target for COVID-19.
Scientists explore whether the anti-stress drug, 4-Phenylbutiric acid (4-PBA), could prevent cytokine storms causing respiratory failure in COVID-19 patients.
The non-infectious quantum dot probes are designed to enable researchers to safely study interactions between the SARS-CoV-2 Spike (S) protein and human cells.
SARS-CoV-2 entry into human cells is dependent on heparan sulfate and disrupting this interaction using heparin reduces infectivity of the coronavirus, find scientists.
Researchers studying the PLpro binding site of three coronaviruses, including SARS-CoV-2, say the BL2 loop could be targeted by antiviral drugs.
In human cells, a drug candidate called PF-00835231 has demonstrated success at blocking the reproduction of SARS-CoV-2.
As the global COVID-19 situation is rapidly changing, staying abreast with the latest news can be challenging. In this article, Sheraz Gul provides an overview of the broad range of potential treatments in development and discusses how the regulatory landscape can shift at any time.